abstract |
The present invention provides an intervertebral disc herniation therapeutic agent which has an extremely low side effect and is administered only once, that is, an effect of improving pain for a long period of time and a clinically high therapeutic effect and safety. The present invention relates to a therapeutic agent for disc herniation using chondroitinase ABC as an active ingredient, which is administered to a human intervertebral disc in 1 to 8 units per disc. |